Analysts Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Target Price at $54.25
Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the stock, ...
Novo Nordisk to phase out human insulin pens: report
Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.
drugdeliverybusiness22h
The biggest diabetes tech stories of the year so far
On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.
Barclays Forecasts Strong Price Appreciation for Tandem Diabetes Care (NASDAQ:TNDM) Stock
Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its target price boosted by Barclays from $58.00 to $60.00 in a research ...